NurExone Biologic Announces U.S. Uplisting Intention and Closes C$2.3 Million Private Placement
NurExone Biologic has successfully closed a non-brokered private placement, raising C$2.3 million through the issuance of 3,543,238 units at C$0.65 per unit. Each unit includes one common share and one warrant, with warrants exercisable at C$0.85 per share for 36 months.
The company plans to utilize the proceeds for working capital, establishing an ExoTop U.S. production facility, and pursuing an uplisting to a major U.S. exchange, subject to regulatory approval. The securities issued are subject to a four-month and one-day statutory hold period.
NurExone Biologic ha concluso con successo un collocamento privato non mediato, raccogliendo C$2,3 milioni attraverso l'emissione di 3.543.238 unità a C$0,65 per unità. Ogni unità comprende una azione comune e un warrant, con warrant esercitabili a C$0,85 per azione per 36 mesi.
L'azienda prevede di utilizzare i proventi per il capitale circolante, per la creazione di un stabilimento di produzione ExoTop negli Stati Uniti e per perseguire un uplisting su una borsa statunitense importante, soggetto ad approvazione normativa. I titoli emessi sono soggetti a un periodo di blocco statutario di quattro mesi e un giorno.
NurExone Biologic ha cerrado con éxito una colocación privada no mediada, recaudando C$2.3 millones a través de la emisión de 3,543,238 unidades a C$0.65 por unidad. Cada unidad incluye una acción común y un warrant, con warrants ejercitables a C$0.85 por acción durante 36 meses.
La compañía planea utilizar los ingresos para capital de trabajo, establecer una instalación de producción ExoTop en EE. UU. y buscar un uplisting en una bolsa importante de EE. UU., sujeto a la aprobación regulatoria. Los valores emitidos están sujetos a un período de retención legal de cuatro meses y un día.
NurExone Biologic는 중개인 없이 성공적으로 사모 배정을 완료하고 C$2.3 백만을 조달했습니다. 이는 C$0.65에 3,543,238 유닛을 발행한 것입니다. 각 유닛에는 하나의 보통주와 하나의 워런트가 포함되어 있으며, 워런트는 36개월 동안 주당 C$0.85에 행사할 수 있습니다.
회사는 자금을 운전 자본, 미국 ExoTop 생산 시설 설립 및 주요 미국 거래소로의 상장 추진에 사용할 계획이며, 이는 규제 승인을 조건으로 합니다. 발행된 증권은 4개월 1일의 법정 보유 기간이 적용됩니다.
NurExone Biologic a réussi à clôturer un placement privé non intermédié, levant C$2,3 millions par l'émission de 3 543 238 unités à C$0,65 par unité. Chaque unité comprend une action ordinaire et un bon de souscription, les bons étant exerçables à C$0,85 par action pendant 36 mois.
La société prévoit d'utiliser les produits pour le fonds de roulement, établir une installation de production ExoTop aux États-Unis et poursuivre un uplisting sur une grande bourse américaine, sous réserve de l'approbation réglementaire. Les titres émis sont soumis à une période de blocage légale de quatre mois et un jour.
NurExone Biologic hat erfolgreich eine nicht vermittelte Privatplatzierung abgeschlossen und C$2,3 Millionen durch die Ausgabe von 3.543.238 Einheiten zu je C$0,65 pro Einheit gesammelt. Jede Einheit umfasst eine Stammaktie und einen Warrant, wobei Warrants für 36 Monate zu C$0,85 pro Aktie ausgeübt werden können.
Das Unternehmen plant, die Erlöse für Betriebskapital, die Errichtung einer ExoTop Produktionsstätte in den USA und die Verfolgung eines Listings an einer wichtigen US-Börse zu verwenden, vorbehaltlich der behördlichen Genehmigung. Die ausgegebenen Wertpapiere unterliegen einer gesetzlichen Haltedauer von vier Monaten und einem Tag.
- Successful fundraising of C$2.3M strengthens financial position
- Planned expansion with new U.S. production facility
- Strategic initiative to uplist to major U.S. exchange
- Strong investor support demonstrated through private placement completion
- Dilution of existing shareholders through new share issuance
- Regulatory approval still pending for TSXV and uplisting
- Additional capital may be needed for U.S. expansion and uplisting costs
TORONTO and HAIFA, Israel, April 04, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX, OTCQB: NRXBF, Germany: J90) (“NurExone” or the “Company”) is pleased to announce that, subject to TSX Venture Exchange (“TSXV”) approval, it has closed a non-brokered private placement of 3,543,238 units (“Units”) at a price of C
CEO Dr. Lior Shaltiel commented, “We sincerely appreciate the strong support from our investors. Our preclinical results and growing analyst recognition underscore the strength of our science and the credibility of our strategy and team. Our momentum is translating into tangible investor confidence, enabling us to secure funding and accelerate our progress towards clinical and commercial breakthroughs in regenerative medicine.”
CFO Eran Ovadya added: “This successful financing marks a significant milestone for NurExone as we expand our operational footprint and strengthen our financial position. The proceeds will be instrumental in supporting our strategic initiatives, including the establishment of a U.S. facility, which will enhance our presence in key markets and further align us with our long-term growth objectives and intent to uplist to a major U.S. exchange.”
Terms of the Offering
Each Unit consisted of (i) one common share in the capital of the Company (each, a “Common Share”), and (ii) one Common Share purchase warrant (each, a “Warrant”). Each Warrant entitles the holder thereof to purchase one Common Share at a price of C
Closing of the Offering is subject to receipt of all necessary regulatory approvals, including TSXV, and all securities issued under the Offering are subject to a statutory hold period of four months and one day from the closing of the Offering and applicable U.S. legends.
About NurExone
NurExone Biologic Inc. is a TSXV, OTCQB and Frankfurt-listed biotech company focused on developing regenerative exosome-based therapies for central nervous system injuries. Its lead product, ExoPTEN, has demonstrated strong preclinical data supporting clinical potential in treating acute spinal cord and optic nerve injury, both multi-billion-dollar marketsi. Regulatory milestones, including Orphan Drug Designation, facilitate the roadmap towards clinical trials in the U.S. and Europe. Commercially, the Company is expected to offer solutions to companies interested in quality exosomes and minimally invasive targeted delivery systems for other indications. NurExone has established Exo-Top Inc., a U.S. subsidiary, to anchor its North American activity and growth strategy.
For additional information and a brief interview, please watch Who is NurExone?, visit www.nurexone.com or follow NurExone on LinkedIn, Twitter, Facebook, or YouTube.
For more information, please contact:
Dr. Lior Shaltiel
Chief Executive Officer and Director
Phone: +972-52-4803034
Email: info@nurexone.com
Oak Hill Financial Inc.
2 Bloor Street, Suite 2900
Toronto, Ontario M4W 3E2
Investor Relations – Canada
Phone: +1-647-479-5803
Email: info@oakhillfinancial.ca
Dr. Eva Reuter
Investor Relations – Germany
Phone: +49-69-1532-5857
Email: e.reuter@dr-reuter.eu
Allele Capital Partners
Investor Relations – U.S.
Phone: +1 978-857-5075
Email: aeriksen@allelecapital.com
FORWARD-LOOKING STATEMENTS
This press release contains certain “forward-looking statements” that reflect the Company’s current expectations and projections about its future results. Wherever possible, words such as “may”, “will”, “should”, “could”, “expect”, “plan”, “intend”, “anticipate”, “believe”, “estimate”, “predict” or “potential” or the negative or other variations of these words, or similar words or phrases, have been used to identify these forward-looking statements. Forward-looking statements in this press release include, but are not limited to, statements relating to: the Company completing the Offering on the terms indicated herein; the Company receiving all regulatory approvals; the use of proceeds from the Offering; the Company the Company advancing towards clinical and commercial breakthroughs in regenerative medicine; the Company enhancing its presence in key markets; the Company’s plan to pursue an uplisting and the benefits thereof; and the NurExone platform technology offering novel solutions to drug companies interested in minimally invasive targeted drug delivery for other indications.
These statements reflect management’s current beliefs and are based on information currently available to management as at the date hereof. In developing the forward-looking statements in this press release, we have applied several material assumptions, including: the Company realizing on the benefits of exosomes; the Company will produce and supply exosomes for a wide range of applications; the ability of the Company’s products to be used for patient treatment; the Company fulfilling its intended future plans and expectations; there being growing clinical demand for innovative treatments in spinal cord, optic nerve, and other therapeutic areas; the Company carrying out its pre-clinical trials and realizing upon the benefits of the pre-clinical trials; the Company’s realizing upon the potential for exosome-loaded drugs in regenerating or repairing damaged nerves; the Company maintaining its ongoing commitment to using its ExoTherapy platform to advance the field of regenerative medicine and cell therapy applications; the Company will complete the Offering on the terms indicated herein; the Company will receive all regulatory approvals; the Company will use the proceeds from the Offering as outlined herein; the Company will have clinical and commercial breakthroughs in regenerative medicine; the Company will enhance its presence in key markets; the Company will uplist to a major U.S. exchange and realize on the benefits thereof; and the NurExone platform technology will offer novel solutions to drug companies interested in minimally invasive targeted drug delivery for other indications.
Forward-looking statements involve significant risk, uncertainties and assumptions. Many factors could cause actual results, performance or achievements to differ materially from the results discussed or implied in the forward-looking statements. These risks and uncertainties include, but are not limited to risks related to: the Company’s early stage of development; lack of revenues to date; government regulation; market acceptance for its products; rapid technological change; dependence on key personnel; dependence on the Company’s strategic partners; the fact that preclinical drug development is uncertain, and the drug product candidates of the Company may never advance to clinical trials; the fact that results of preclinical studies and early-stage clinical trials may not be predictive of the results of later stage clinical trials; the uncertain outcome, cost, and timing of product development activities, preclinical studies and clinical trials of the Company; the uncertain clinical development process, including the risk that clinical trials may not have an effective design or generate positive results; the inability to obtain or maintain regulatory approval of the drug product candidates of the Company; the introduction of competing drugs that are safer, more effective or less expensive than, or otherwise superior to, the drug product candidates of the Company; the initiation, conduct, and completion of preclinical studies and clinical trials may be delayed, adversely affected or impacted by unforeseen issues; the inability to obtain adequate financing; the inability to obtain or maintain intellectual property protection for the drug product candidates of the Company; risks that the Company’s intellectual property and technology won’t have the intended impact on the Company and/or its business; the Company’s inability to carry out its pre-clinical trials and realize upon the stated benefits of the pre-clinical trials; the inability of the Company to realize on the benefits of exosomes; the inability of the Company to produce and/or supply exosomes for a wide range of applications; the inability of the Company’s products to be used for patient treatment; there not being broader adoption in the field and/or cell therapy applications; the inability of the Company to fulfill its intended future plans and expectations; there not being growing clinical demand for innovative treatments in spinal cord, optic nerve, and/or other therapeutic areas; the inability of the Company to collaborate with pharma companies; the Company’s inability to realize upon the stated potential for exosome-loaded drugs in regenerating or repairing damaged nerves; the Company’s inability to maintain its ongoing commitment to using its ExoTherapy platform to advance the field of regenerative medicine and/or cell therapy applications; the Company’s inability to expand into further studies; the Company’s inability to complete the Offering on the terms indicated herein or at all; the Company will not receive all required regulatory approvals; the Company will not use the proceeds from the Offering as outlined herein; the Company will not have clinical and/or commercial breakthroughs in regenerative medicine; the Company will be unable to enhance its presence in key markets; the Company will not uplist to a major U.S. exchange and/or realize on the benefits thereof; the NurExone platform technology not offering novel solutions to drug companies interested in minimally invasive targeted drug delivery for other indications; and the risks discussed under the heading “Risk Factors” on pages 44 to 51 of the Company’s Annual Information Form dated August 27, 2024, a copy of which is available under the Company’s SEDAR+ profile at www.sedarplus.ca. These factors should be considered carefully, and readers should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, the Company cannot assure readers that actual results will be consistent with these forward-looking statements. These forward-looking statements are made as of the date of this press release, and the Company assumes no obligation to update or revise them to reflect new events or circumstances, except as required by law.
Neither TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.
i Spinal cord injury, Glaucoma
FAQ
How much did NurExone Biologic (NRXBF) raise in their latest private placement?
What are the terms of NRXBF's April 2025 private placement warrants?
How will NurExone (NRXBF) use the proceeds from their C$2.3M placement?
What is the hold period for securities from NRXBF's April 2025 private placement?
